China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand their one-stop oral soluble film research and development (R&D) and production services. The collaboration aims to enhance their capabilities in this innovative drug delivery system, with no financial details disclosed.
Advantages of Oral Soluble Films
Oral soluble films are a new drug delivery system that offers flexible dosing, ease of use, and avoids the first-pass effect. They are primarily developed for use in children, the elderly, special patients, and emergency drugs. The Center for Drug Evaluation (CDE) released the “Technical Guidelines for Clinical Trials of Modified New Chemicals (draft proposal)” in June 2020, explicitly encouraging the development of oral soluble films and other modified drugs. Companies such as Qilu Pharma, Hengrui Medicine, and Kelun Pharma also have products of this kind under review in China.
Company Backgrounds
Founded in 2016, HQ Pharma is focused on the R&D of high-end modified preparations based on drug delivery systems. HCXF Pharma, established in November 2000, boasts an annual production capacity of 300 million oral soluble film preparations. This partnership combines their expertise to drive innovation and meet the growing demand for advanced drug delivery solutions.
Significance of the Collaboration
The collaboration between HQ Pharma and HCXF Pharmaceutical highlights the commitment of both companies to advancing innovative drug delivery technologies. By combining their strengths, they aim to accelerate the development and production of oral soluble films, offering improved treatment options for various patient populations.-Fineline Info & Tech
